Sigyn Therapeutics, Inc. has issued a shareholder update detailing its exploration of strategic transactions including potential mergers and asset sales. The company, which develops dialysis-like therapies for cardiovascular disease and cancer, faces challenges after an unsuccessful attempt to uplist from the OTCQB market to Nasdaq.
CEO Jim Joyce, who previously founded Aethlon Medical and oversaw development of the FDA-cleared Hemopurifier device, explained that Sigyn's current OTC status has impacted the company's ability to raise capital without harming shareholder value. The company's CardioDialysis therapy targets cholesterol-transporting lipoproteins and inflammatory molecules, positioning it as a potential treatment for cardiovascular disease, sepsis, and traumatic brain injury.
The company's therapeutic approach addresses significant healthcare challenges. Cardiovascular disease remains the leading cause of death worldwide, and current lipoprotein apheresis treatments are limited to fewer than 60 specialized centers in the United States. CardioDialysis is designed for use on existing dialysis machines at more than 7,500 U.S. clinics, potentially expanding access to treatment.
For sepsis, which represents the leading cause of in-hospital mortality, Sigyn's technology has been validated to reduce sepsis-inducing bacterial toxins and inflammatory mediators. The company notes that Spectral Medical, with a market value of approximately $300 million, is advancing the PMX hemoadsorption device through clinical studies for sepsis treatment.
Joyce detailed the challenges encountered during the Nasdaq uplist attempt, describing a regulatory "catch-22" where Nasdaq requested investor approval before SEC registration statement effectiveness, while SEC required contingent Nasdaq listing approval before deeming the registration effective. This led to withdrawal of the registration statement and cancellation of the planned financing.
The company is now exploring alternative strategies, including the potential sale of certain assets and a merger with a Nasdaq-listed company at risk of not meeting the forthcoming $5 million minimum market value of listed securities requirement. Additional details about these strategies are available in the company's January 15th shareholder update.
Sigyn's pipeline includes CardioDialysis for cardiovascular disease, ImmunePrep for cancer immunotherapy optimization, ChemoPrep for targeted chemotherapy delivery, and ChemoPure for chemotherapy toxicity reduction. The company had 2,330,042 shares outstanding as of March 11, 2026.
The strategic shift comes as Sigyn seeks to advance its therapies while addressing capital market challenges. The company's technologies target significant unmet medical needs, with cardiovascular disease affecting millions globally and sepsis representing a critical hospital challenge. The outcome of Sigyn's strategic initiatives could influence how early-stage medical technology companies navigate public markets while developing potentially transformative therapies.
